

Effect of Wnt5a on drug resistance in estrogen receptor-positive breast cancer

Ai Amioka¹⁾, Takayuki Kadoya¹⁾, Satoshi Sueoka¹⁾, Yoshie Kobayashi¹⁾, Shinsuke Sasada¹⁾, Akiko Emi¹⁾, Norio Masumoto¹⁾, Masaoki Ito¹⁾, Koh Nakayama²⁾, Morihito Okada¹⁾

1) Department of Surgical Oncology, Research Institute for Radiation Biology and

Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima 734-8551,

Japan

2) Oxygen Biology Laboratory, Medical Research Institute, Tokyo Medical and Dental

University, Bunkyo-ku, Tokyo 113-8510, Japan

Corresponding author:

Takayuki Kadoya, M.D, Ph.D

Email: takayukikadoya@gmail.com

Tel.: +81-082-257-5869

Fax: +81-082-256-7109

Online Resource 3

Postoperative treatment of recurrent cases of ER-positive breast cancer

Cases	Wnt5a expression	Adjuvant chemotherapy	Adjuvant hormone therapy
1	positive	–	TAM
2	positive	–	TAM, LH-RHa
3	positive	–	AI
4	positive	TC	AI
5	positive	FEC+DTX	–
6	negative	TC	AI

Abbreviations: TAM, Tamoxifen; LH-RHa, Luteinizing hormone-releasing hormone agonist; AI, Aromatase inhibitor; TC, Docetaxel + Cyclophosphamide; FEC, 5-Fluorouracil + Epirubicin + Cyclophosphamide; DTX, Docetaxel.